ARTICLE IN PRESSTHE JOURNAL01UROLOGYCheck forAUA Guideline Articlewww.auajournals.org/journal/juroupdatesDiagnosis and Management of Non-Metastatic UpperTract Urothelial Carcinoma:AUA/SUO GuidelineJonathan A.Coleman,1*Peter E.Clark,2 Brooke R.Bixler,3 David I.Buckley,4 Sam S.Chang,5Roger Chou,4 Jean Hoffman-Censits,5 Girish S.Kulkarni,7 Surena F.Matin,3 Phillip M.Pierorazio,3Aaron M.Potretzke,10 Sarah P.Psutka,11 Jay D.Raman,12 Angela B.Smith,13 and Laura Smith14'Memorial Sloan Kettering Cancer Center,New York,New YorkDepartment of Urology,Atrium Health,Charlotte,North Carolina3American Urological Association,Linthicum,MarylandPacific Northwest Evidence-based Practice Center,Oregon Health Science University,Portland,OregonDepartment of Urology,Vanderbilt Health,Nashville,TennesseeDepartment of Oncology,Johns Hopkins Medicine,Baltimore,MarylandDivision of Urology.University of Toronto,Toronto,Ontario,CanadaDepartment of Urology,MD Anderson Cancer Center,Houston,TexasDepartment of Urology,Penn Medicine,Philadelphia,Pennsylvania1Department of Urology,Mayo Clinic,Rochester,MinnesotaDepartment of Urology,University of Washington Medicine,Seattle,Washington12Division of Urology,Penn State Health,Hershey,PennsyvaniaDepartment of Urology,University of North Carolina School of Medicine,ChapelHll North Carolina14Saratoga Springs,New YorkPurpose:The purpose of this guideline is to provide a useful reference on theeffective evidence-based diagnoses and management of non-metastatic uppertract urothelial carcinoma (UTUC).Materials/Methods:The Pacific Northwest Evidence-based Practice Center ofOregon Health Science University (OHSU)team conducted searches in OvidMEDLINE (1946 to March 3rd,2022),Cochrane Central Register of ControlledTrials (through January 2022),and Cochrane Database of Systematic Reviews(through January 2022).The searches were updated August 2022.When suffi-cient evidence existed,the body of evidence was assigned a strength rating of A(high),B(moderate),or C(low)for support of Strong,Moderate,or ConditionalRecommendations.In the absence of sufficient evidence,additional informationis provided as Clinical Principles and Expert Opinions (Table 1).Results:This Guideline provides updated,evidence-based recommendationsregarding diagnosis and management of non-metastatic UTUC including riskstratification,surveillance and survivorship.Treatments discussed include kid-ney sparing management,surgical management,lymph node dissection(LND),neoadjuvant/adjuvant chemotherapy and immunotherapy.Conclusion:This standardized guideline seeks to improve clinicians'ability toevaluate and treat patients with UTUC based on available evidence.Futurestudies will be essential to further support these statements for improving pa-tient care.Updates will occur as the knowledge regarding disease biology,clin-ical behavior and new therapeutic options develop.Submitted April 5.2023:accepted April 6.2023:published 000.The complete unabridged version of the guideline is avail
